Emami Limited
Quality (79/100) does the heavy lifting; momentum (11/100) is the drag.
Fair valueOvervaluedOur blended model reads Emami Limited as a Sell at 37/100. On 22.7x trailing earnings it sits cheaper than the Consumer Defensive median of about 26.1x. It's sitting close to its 52-week low of ₹384.8. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹545.05 implies about 37% upside across 22 analysts. It clears 6 of 13 investability checks, with durability 79, valuation 45 and momentum 11 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹227.48.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-35.21% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell37Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 27.6%
- Pass: Low debt (D/E < 0.5): 0.06x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -4%
- Fail: Earnings growing: -12%
- Pass: Net margin ≥ 10%: 20.5%
- Pass: Current ratio > 1.5: 2.31
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 13.67
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter57.3%
- Institutions32.6%
- Public & other10.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (27.6%).
- Lightly leveraged balance sheet.
- Healthy profit margin (20.5%).
- Financially solid — Altman Z 13.67.
Opportunities
- Well off its 52-week high — possible mean-reversion.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
- Trades ~29% above our estimated fair value.
About Emami Limited
Emami Limited manufactures and markets personal and healthcare products across India and international markets. Its portfolio includes BoroPlus antiseptic cream, body lotion, prickly heat powder, petroleum jelly, soaps, and aloe vera gel; Navratna oil and cool talc; and ayurvedic products for pain management, immunity, digestive health, and bone and joint care, alongside hair growth vitalizers and skincare items.
Emami Limited — frequently asked questions
Is Emami Limited a buy, hold or sell?
StocksWizard currently rates Emami Limited (EMAMILTD) a Sell, based on a blended score of 37/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Emami Limited's fair value?
Our blended DCF and relative-valuation model estimates Emami Limited's fair value at about ₹284.36, versus a current price of ₹398.05 — roughly 29% downside. On that basis the stock looks overvalued by 29%.
Is Emami Limited financially healthy?
Emami Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Emami Limited's share price performed?
Emami Limited is down 12% over three months, and last traded at ₹398.05. Past performance doesn't predict future returns.
More in Consumer Defensive
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.